Brentuximab Vedotin
Brentuximab vedotin regimen lowers relapse risk in pediatric high-risk Hodgkin lymphoma
The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results.
Highlights from ASCO Annual Meeting 2022
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.
Brentuximab regimen effective for younger patients with advanced-stage Hodgkin lymphoma
CHICAGO — Combining brentuximab vedotin with a chemotherapy regimen as first-line therapy conferred an objective response in 88% of younger patients with newly diagnosed advanced-stage classical Hodgkin lymphoma, study results show.
First-line brentuximab vedotin regimen extends OS in advanced classical Hodgkin lymphoma
CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients with advanced classical Hodgkin lymphoma, according to study results presented at ASCO Annual Meeting.
Addition of brentuximab vedotin to chemotherapy extends OS in advanced Hodgkin lymphoma
Brentuximab vedotin shows promise in high-risk pediatric Hodgkin lymphoma
The replacement of vincristine with brentuximab vedotin in standard front-line treatment appeared safe and effective among children and adolescents with high-risk classical Hodgkin lymphoma, according to phase 2 study results.
VIDEO: Treatment for older Hodgkin lymphoma patients is ‘an area of unmet need’
Brentuximab vedotin alone may not be a good option for older patients with Hodgkin lymphoma; however, brentuximab seems a reasonable choice when used in combination with other therapies, like dacarbazine.
VIDEO: Post-transplant consolidation with nivolumab, brentuximab shows promise in Hodgkin lymphoma
Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation showed promise in patients with high-risk Hodgkin lymphoma, according to a presentation at the ASH Annual Meeting and Exposition.
VIDEO: Romidepsin, brentuximab vedotin shows promise in cutaneous T-cell lymphoma
Romidepsin combined with brentuximab vedotin was well-tolerated in patients requiring systemic therapy for cutaneous T-cell lymphoma, according to phase 1 data presented at ASH Annual Meeting and Exposition.
Late effects of Hodgkin lymphoma treatment: We can still do better
In more than 6 years as a chief medical editor for HemOnc Today, only a few subjects have prompted me to write more than one editorial.